On-Demand Therapy for Gastroesophageal Reflux Disease

The following pages summarize the proceedings of a symposium held in May 2006 on the emerging role of on-demand therapy for gastroesophageal reflux disease (GERD). Medical therapy for GERD has undergone significant change in recent years with the advent of effective, but expensive, antisecretory agents. On-demand (patient-driven) therapy is attractive to payers and patients, because it appears to be both cost-effective and convenient. Many individuals appear to accept occasional symptomatic breakthrough in exchange for personal control of their disease. On-demand therapy should be distinguished from intermittent therapy, which is either patient- or physician-driven, but which requires intermittent episodes of continuous therapy followed by discontinuation until symptoms recur. Proton pump inhibitors appear to be effective on-demand agents despite theoretical pharmacodynamic limitations for this class of drug. The available data support the use of on-demand therapy for GERD in uninvestigated reflux disease, nonerosive reflux disease, and possibly mild esophagitis as well. On-demand therapy should not be considered for patients with severe esophagitis.

[1]  P. Malfertheiner,et al.  A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[3]  G. Sachs,et al.  Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.

[4]  C. Howden,et al.  Review article: immediate‐release proton‐pump inhibitor therapy – potential advantages , 2005, Alimentary pharmacology & therapeutics.

[5]  E. Savarino,et al.  Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group , 2005, The American Journal of Gastroenterology.

[6]  T. Scholten,et al.  On-Demand Therapy with Pantoprazole 20 mg as Effective Long-Term Management of Reflux Disease in Patients with Mild GERD: The ORION Trial , 2005, Digestion.

[7]  L. Kupčinskas,et al.  Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease , 2005, European journal of gastroenterology & hepatology.

[8]  E. Remák,et al.  Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK* , 2005, Current medical research and opinion.

[9]  E. Toth,et al.  Daily treatment with esomeprazole is superior to that taken on‐demand for maintenance of healed erosive oesophagitis , 2005, Alimentary pharmacology & therapeutics.

[10]  R. Bagin,et al.  Comparison of the effects of immediate‐release omeprazole powder for oral suspension and pantoprazole delayed‐release tablets on nocturnal acid breakthrough in patients with symptomatic gastro‐oesophageal reflux disease , 2005, Alimentary pharmacology & therapeutics.

[11]  P. Wahlqvist,et al.  Six‐month management of patients following treatment for gastroesophageal reflux disease symptoms – a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting , 2005, International journal of clinical practice.

[12]  J. Zacny,et al.  Systematic review: the efficacy of intermittent and on‐demand therapy with histamine H2‐receptor antagonists or proton pump inhibitors for gastro‐oesophageal reflux disease patients , 2005, Alimentary pharmacology & therapeutics.

[13]  M. Fennerty,et al.  Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease? , 2004, Alimentary pharmacology & therapeutics.

[14]  A. Blum,et al.  Rationale and proposed algorithms for symptom‐based proton pump inhibitor therapy for gastro‐oesophageal reflux disease , 2004, Alimentary pharmacology & therapeutics.

[15]  H. H. Juhl,et al.  Costs and efficacy of three different esomeprazole treatment strategies for long‐term management of gastro‐oesophageal reflux symptoms in primary care , 2004, Alimentary pharmacology & therapeutics.

[16]  A. Barkun,et al.  The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study , 2003, Alimentary pharmacology & therapeutics.

[17]  B. Goldlust,et al.  Comparative effects of an omeprazole antacid complex-immediate release (OAC-IR) and omeprazole-delayed release (OME-DR) on omeprazole pharmacokinetics (PK) and gastric pH in healthy subjects , 2003 .

[18]  P. Bytzer Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients , 2003, American Journal of Gastroenterology.

[19]  T. Lind,et al.  Sufficient control of heartburn in endoscopy‐negative gastro‐oesophageal reflux disease trials , 2003, Scandinavian journal of gastroenterology.

[20]  Clifford Goodman,et al.  The burden of selected digestive diseases in the United States. , 2002, Gastroenterology.

[21]  M. Simrén,et al.  On-Demand Treatment in Patients with Oesophagitis and Reflux Symptoms: Comparison of Lansoprazole and Omeprazole , 2002, Scandinavian journal of gastroenterology.

[22]  T. Levin,et al.  Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a Health Maintenance Organization , 2000, American Journal of Gastroenterology.

[23]  John Hornberger,et al.  A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease , 2000, American Journal of Gastroenterology.

[24]  L. Lachman,et al.  Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration , 2000, American Journal of Gastroenterology.

[25]  A. Hungin,et al.  Long-term prescribing of proton pump inhibitors in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[26]  A. Hungin,et al.  Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. , 1999, The British journal of general practice : the journal of the Royal College of General Practitioners.

[27]  E. El-Omar,et al.  Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers(Fig. 1) , 1999, American Journal of Gastroenterology.

[28]  A. Blenkinsopp,et al.  The rise and rise of proton pump inhibitor drugs: patients' perspectives. , 1997, Social science & medicine.

[29]  R. Pounder,et al.  Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: a placebo-controlled, double-blind study. , 1991, Gastroenterology.

[30]  R. Pounder,et al.  Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. , 1991, Gastroenterology.

[31]  S. Sontag The medical management of reflux esophagitis. Role of antacids and acid inhibition. , 1990, Gastroenterology clinics of North America.

[32]  C. Wilder-Smith,et al.  Tolerance to oral H2-receptor antagonists , 1990, Digestive Diseases and Sciences.

[33]  C. Wilder-Smith,et al.  Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients. , 1990, Gut.

[34]  D. Johnston,et al.  The effect of food on ranitidine‐induced inhibition of nocturnal gastric secretion , 1988, Alimentary pharmacology & therapeutics.

[35]  R. Hunt,et al.  Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist. , 1988, Gut.

[36]  G. Sachs,et al.  Review article: the clinical pharmacology of proton pump inhibitors , 2006, Alimentary pharmacology & therapeutics.

[37]  R. Hunt,et al.  Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[38]  J. Richter,et al.  Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. , 1997, The American journal of medicine.

[39]  P. Reinikainen,et al.  Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. , 1997, The American journal of gastroenterology.

[40]  A. Sandvik,et al.  The intensity and variability of symptoms in dyspepsia. , 1993, Scandinavian journal of primary health care.

[41]  R. Pounder,et al.  Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. , 1990, Alimentary pharmacology & therapeutics.

[42]  R. Pounder,et al.  Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. , 1990, Alimentary pharmacology & therapeutics.

[43]  J. Misiewicz Clinical relevance of tolerance to peptic ulcer healing and relapse. , 1990, Alimentary pharmacology & therapeutics.

[44]  Misiewicz Jj Clinical relevance of tolerance to peptic ulcer healing and relapse. , 1990 .